Drug interactions of zonisamide with phenytoin and sodium valproate: serum concentrations and protein binding. 1995

K Tasaki, and T Minami, and I Ieiri, and K Ohtsubo, and Y Hirakawa, and K Ueda, and S Higuchi
Department of Pediatrics, Faculty of Medicine, Kyushu University, Fukuoka, Japan.

The influence of co-medication with zonisamide (ZNS) on the serum concentration and protein binding of phenytoin (PHT) and sodium valproate (VPA) was studied in 21 pediatric patients. No significant correlation between the daily ZNS dose, and total serum concentrations, free concentrations or free fractions (FF) of PHT or VPA was observed. The patient study showed that changes in the FF of PHT and VPA were correlated more closely with the serum protein and bilirubin levels than changes in the ZNS dosage. An in vitro study revealed that the addition of ZNS caused decreases in the FF of PHT and VPA. However, these decreases were within the range of measurement error and were negligible. In conclusion, no significant effect of ZNS on the serum concentration or protein binding of PHT or VPA was demonstrated.

UI MeSH Term Description Entries
D007555 Isoxazoles Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions. Isoxazole
D010672 Phenytoin An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs. Diphenylhydantoin,Fenitoin,Phenhydan,5,5-Diphenylhydantoin,5,5-diphenylimidazolidine-2,4-dione,Antisacer,Difenin,Dihydan,Dilantin,Epamin,Epanutin,Hydantol,Phenytoin Sodium,Sodium Diphenylhydantoinate,Diphenylhydantoinate, Sodium
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D004827 Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) Aura,Awakening Epilepsy,Seizure Disorder,Epilepsy, Cryptogenic,Auras,Cryptogenic Epilepsies,Cryptogenic Epilepsy,Epilepsies,Epilepsies, Cryptogenic,Epilepsy, Awakening,Seizure Disorders
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000078305 Zonisamide A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization. 3-Sulfamoylmethyl-1,2-benzisoxazole,AD 810,AD-810,CI 912,CI-912,Zonegran,Zonisamide Monosodium,3 Sulfamoylmethyl 1,2 benzisoxazole,AD810,CI912

Related Publications

K Tasaki, and T Minami, and I Ieiri, and K Ohtsubo, and Y Hirakawa, and K Ueda, and S Higuchi
January 1980, Monographs in neural sciences,
K Tasaki, and T Minami, and I Ieiri, and K Ohtsubo, and Y Hirakawa, and K Ueda, and S Higuchi
January 1980, Clinical pharmacology and therapeutics,
K Tasaki, and T Minami, and I Ieiri, and K Ohtsubo, and Y Hirakawa, and K Ueda, and S Higuchi
January 1980, Journal of clinical pharmacology,
K Tasaki, and T Minami, and I Ieiri, and K Ohtsubo, and Y Hirakawa, and K Ueda, and S Higuchi
February 1978, Il Farmaco; edizione pratica,
K Tasaki, and T Minami, and I Ieiri, and K Ohtsubo, and Y Hirakawa, and K Ueda, and S Higuchi
February 1982, Neuropediatrics,
K Tasaki, and T Minami, and I Ieiri, and K Ohtsubo, and Y Hirakawa, and K Ueda, and S Higuchi
February 1986, Journal of clinical pharmacology,
K Tasaki, and T Minami, and I Ieiri, and K Ohtsubo, and Y Hirakawa, and K Ueda, and S Higuchi
April 1986, The Indian journal of medical research,
K Tasaki, and T Minami, and I Ieiri, and K Ohtsubo, and Y Hirakawa, and K Ueda, and S Higuchi
March 1986, Journal of neurology, neurosurgery, and psychiatry,
K Tasaki, and T Minami, and I Ieiri, and K Ohtsubo, and Y Hirakawa, and K Ueda, and S Higuchi
February 1984, Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis,
K Tasaki, and T Minami, and I Ieiri, and K Ohtsubo, and Y Hirakawa, and K Ueda, and S Higuchi
March 2007, Epilepsia,
Copied contents to your clipboard!